finance.yahoo.com ·
Tg Therapeutics Inc Q1 2026
Topic context
This topic has been covered 273991 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedTG Therapeutics reported record Q1 BRIUMVI sales and raised guidance. The $100M manufacturing investment is a concrete capex signal for biotech/pharma sector. Impact is company-specific; no broader commodity or supply chain disruption.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 BRIUMVI revenue $195M in U.S.
- FY2026 global revenue guidance raised to ~$925M
- One-time $9.2M refinancing charge
- $100M investment in subcutaneous manufacturing
- Phase III ENHANCE data anticipated
BRIUMVI revenue impact is flat in the short term due to already raised guidance; confidence level is moderate.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
Nextera Dominion Energy Merger Create
finance.yahoo.com
Ascend Wellness Q1 Earnings Call
finance.yahoo.com
Eurodry Edry Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
economictimes.indiatimes.com